logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
F

Fei Liang

fudan university
H指数:34
被引数:4,101

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of external drainage of the main pancreatic duct and common bile duct on postoperative pancreatic fistula following pancreatoduodenectomy: protocol for a multicentre randomized clinical trial

主要胰管和共同胆管外部引流对胰十二指肠切除术后胰瘘影响：一项多中心随机临床试验方案

BJS OPEN
IF4.5
2025-12-010
OAAI
Wang, Wen-Quan; Xu, Yao-Lin; Tang, Lin-Hui; He, Jun-Yi; Li, Yu; Liang, Fei; Zhang, Yue-Ming; Gan, Wei; Xu, Hua-Xiang; Zhang, Lei; Wu, Wen-Chuan; Shi, Chen-Ye; Jin, Yun; Jiang, Chong-Yi; Wang, Zheng; He, Min; Wang, Xu-An; Qiu, Yu-Dong; Liu, Liang
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial

中国患者术后肝内胆管癌的辅助性卡瑞利珠单抗联合卡培他滨治疗（ACC）：一项单臂、单中心、开放标签、II期临床试验

The Lancet Gastroenterology & Hepatology
IF38.6
2025-11-270
PRE
Zheng Wang; Lixing Li; Peiran Huang; Honghu Tu; Xiangyu Zhang; Lei Yu; Fei Liang; Cheng Huang; Shuangjian Qiu; Qinghai Ye; Zhenbin Ding; Xiaowu Huang; Yinghong Shi; Kang Song; Huichuan Sun; Xiaoying Wang; Yongfeng Xu; Yao Yu; Qiang Gao; Lan Zhang
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial

围手术期卡瑞利珠单抗联合瑞戈非尼 versus 手术单药治疗复发风险为中高危的可切除肝细胞癌患者（CARES-009）：一项随机II/III期试验

The Lancet
IF97.3
2025-10-190
PRE
Zheng Wang; Jia Fan; Shaolai Zhou; Yunfan Sun; Fei Liang; Yuan Ji; Fangming Gu; Tao Li; Li Peng; Tao Peng; Xiaolun Huang; Zhenbin Ding; Dousheng Bai; Bangde Xiang; Guang Tan; Tianfu Wen; Yongyi Zeng; Feng Han; Yu Zhang; Shengdong Wu; Haitao Zhao; Yi Chen; Guoming Shi; Zhiguo Hou; Ying Sun; Wenqing Zhu; Jian Zhou
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study

替雷利珠单抗联合仑伐替尼和GEMOX方案治疗不可切除的局部晚期胆道癌的转化治疗（ZSAB-TransGOLP）：一项多中心、前瞻性、Ⅱ期研究

The Lancet Oncology
IF0
2025-08-290
PRE
Guoming Shi; Xiaoyong Huang; Xiaowu Li; Fei Liang; Qiang Gao; Daohan Zhang; Jiacheng Lu; Yuan Ji; Zhiqiang Hu; Yi Chen; Shuangjian Qiu; Yong Yi; Xiaodong Zhu; Huichuan Sun; Yinghong Shi; MinJie Peng; Xiaoying Wang; Cheng Huang; Zhenbin Ding; Yifeng He; Yinghao Shen; Yongfeng Xu; Yongsheng Xiao; Jie Hu; Jian Zhou; Jia Fan
Androgen induces 3′UTR shortening of de novo lipogenesis genes by alternative polyadenylation in prostate cancer cells

雄激素通过可变多聚腺苷酸化在前列腺癌细胞中诱导从头脂质合成基因的3′UTR缩短。

science china life sciences
IF0
2025-07-080
OA
Wei-Jie Sun; Fei Liang; Hui Zhao; Yun-Mei Wang; Zhong-Yin Zhou; Hui Xu; Hang Liu; Dong Tang; An-Long Xu; Yong-Gui Fu; Xi Li; Jun Ouyang; Newton O. Otecko; Ben-Xia Hu; Teng-Fei Ma; Xin Li; Dong-Dong Wu; Hui Zhao; Ya-Ping Zhang
Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring

围术期纳武利尤单抗联合化疗在局部晚期食管鳞状细胞癌中的应用：一项随机多中心Ⅱ期研究，并监测循环肿瘤DNA动力学

MOLECULAR CANCER
IF33.9
2025-05-150
OA
Jiao, Heng; Lin, Siyun; Gu, Jianmin; Jiang, Dongxian; Cui, Peng; Huang, Zhiliang; Fang, Yong; Wang, Hao; Lin, Miao; Tang, Han; Jiang, Tian; Lin, Guangyi; Zhang, Shaoyuan; Yin, Hao; Liang, Fei; Wang, Jingshu; Fan, Xuning; Qiu, Fujun; Yang, Yang; Li, Zhigang; Li, Bin; Xiang, Jiaqing; Leng, Xuefeng; Han, Yongtao; Li, Chengcheng; Ai, Luoyan; Hou, Yingyong; Zhang, Zhihong; Cai, Shangli; Yin, Jun; Tan, Lijie
Chemotherapy alone versus chemotherapy plus targeted therapy as adjuvant therapy for initially unresectable colorectal cancer liver metastases: a multicenter cohort study

化疗单独与化疗联合靶向治疗作为初始不可切除的结直肠癌肝转移的辅助治疗：一项多中心队列研究

Gastroenterology Report
IF4.2
2025-01-110
OA
Wenju Chang; Shizhao Zhou; Xu Guan; Donghao Xu; Yu Liu; Wentao Tang; Yang Lv; Xiaorui Qin; Fei Liang; Xiaoying Wang; Li Ren; Jia Fan; Ye Wei; Xishan Wang; Jianmin Xu
Safety and efficacy fi cacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after fi rst-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial

第一代EGFR-酪氨酸激酶抑制剂治疗后少残留EGFR突变非小细胞肺癌的巩固立体定向放射治疗的安全性和有效性: 一项单臂2期试验

ECLINICALMEDICINE
IF10
2024-10-011
OAAI
Zhou, Yue; Peng, Lin; Liang, Fei; Chu, Li; Chu, Xiao; Yang, Xi; Zhang, Junhua; Guo, Tiantian; Jiang, Shanshan; Pang, Yechun; Wang, Zezhou; Zhang, Li; Ni, Jianjiao; Zhu, Zhengfei

研究方向

暂未获取到该数据
Y
Yongzhi Xi
H 指数:14论文数:90被引数:609
Y
Yuying Sun
H 指数:10论文数:28被引数:249
N
Nan Liu
H 指数:58论文数:1,128被引数:1.5万
樊
樊嘉
H 指数:126论文数:1,507被引数:6.8万
J
Juan Long
H 指数:13论文数:57被引数:366
赵
赵筱
H 指数:13论文数:77被引数:482
J
Justin Stebbing
H 指数:84论文数:1,076被引数:3.1万
孙
孙会
H 指数:74论文数:540被引数:2.1万
Y
Ye Wei
H 指数:44论文数:363被引数:6,924
高
高强
H 指数:74论文数:498被引数:2.0万